Therefore, we suggest that Bcl-2 antagonists might be helpful in improving cisplatin sensitivity and outcomes in p53-mutant NSCLC patients who harbor high-Nrf2 mRNA tumors. Here, NFE2L2 is linked to non-small cell lung carcinoma.